Market Overview

UPDATE: Sterne Agee Resumes Coverage on Covance with Neutral Rating, $76 PT on Current Valuation

Share:
Related CVD
KeyBanc Starts Lab Corp Of America At Overweight, But Indebtedness Is A Concern
Morgan Stanley Previews Earnings For Cardinal Health, Quest Diagnostics

In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on Covance (NYSE: CVD) with a Neutral rating and $76.00 price target.

In the report, Sterne Agee noted, “CVD possesses the most diversified services portfolio of any CRO, which over the years has insulated the company from heightened volatility in revenue and earnings results. With marked improvement in Central Lab kit volume and mix as well as continued momentum in Clinical results, we think the company will experience accelerating EPS growth. We believe the current valuation reflects our thinking and thus initiate with a Neutral rating and $76 price target.”

Covance closed on Tuesday at $74.91.

Latest Ratings for CVD

DateFirmActionFromTo
Nov 2014CitigroupMaintainsNeutral
Nov 2014KeyBancDowngradesBuyHold
Nov 2014Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for CVD
View the Latest Analyst Ratings

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Initiation Analyst Ratings

 

Related Articles (CVD)

Get Benzinga's Newsletters